Figure 4.

Activation of MAPK1/3 and AKT Pro-survival Pathways

(A–E) Representative western blots and protein levels in ventral midbrain homogenates from mice overexpressing TFEB (n = 6) compared to control mice (n = 5 to 6) of (A) MAPK 1 and 3, their activated forms (pMAPK1/3^{Thr202/Tyr204}), and the ratio; (B) 90-kDa ribosomal protein S6 kinase (P90RSK) and its phosphorylated/activated form (pP90RSK^T359/S363) and the ratio; (C) total AKT and phosphorylated/activated AKT (pAKT^S473) and the ratio; (D) total NDRG1, its phosphorylated/activated form (pNDRG1^T346), and the ratio; and (E) TBK1, its phosphorylated/activated form (pTBK1^S172), and the ratio. Mann-Whitney test, *p < 0.05 compared to control. In all panels, samples were collected 5 weeks after AAV-TFEB or vehicle injections. All data are represented as mean ± SEM.